Skip to main content
Top
Published in: Virology Journal 1/2010

Open Access 01-12-2010 | Review

Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review

Authors: Shushan Zhao, Lanhua Tang, Xuegong Fan, Lizhang Chen, Rongrong Zhou, Xiahong Dai

Published in: Virology Journal | Issue 1/2010

Login to get access

Abstract

Background

Chronic viral hepatitis B remains a global public health concern. Currently, several drugs, such as lamivudine and telbivudine, are recommended for treatment of patients with chronic hepatitis B. However, there are no conclusive results on the comparison of the efficacy of lamivudine (LAM) and telbivudine (LdT) in the treatment of chronic hepatitis B.

Results

To evaluate the comparison of the efficacy of LAM and LdT in the treatment of chronic hepatitis B by a systematic review and meta-analysis of clinical trials, we searched PUBMED (from 1990 to April 2010), Web of Science (from 1990 to April 2010), EMBASE (from 1990 to April 2010), CNKI (National Knowledge Infrastructure) (from 1990 to April 2010), VIP database (from 1990 to April 2010), WANFANG database (from 1990 to April 2010), the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Review. At the end of one-year treatment, LdT was better than LAM at the biochemical response, virological response, HBeAg loss, therapeutic response, while less than at the viral breakthrough and viral resistance, but there was no significant difference in the HBeAg seroconversion and HBsAg response. LdT was better than LAM at the HBeAg seroconversion with prolonged treatment to two years.

Conclusions

In summary, LdT was superior in inhibiting HBV replication and preventing drug resistance as compared to LAM for CHB patients. But LdT may cause more nonspecific adverse events and can lead to more CK elevation than LAM. It is thus recommended that the LdT could be used as an option for patients but adverse events, for example CK elevation, must be monitored.
Appendix
Available only for authorised users
Literature
1.
go back to reference Safioleas M, Lygidakis NJ, Manti C: Hepatitis B today. Hepatogastroenterology 2007, 54: 545-548.PubMed Safioleas M, Lygidakis NJ, Manti C: Hepatitis B today. Hepatogastroenterology 2007, 54: 545-548.PubMed
2.
go back to reference Poland GA, Jacobson RM: Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med 2004, 351: 2832-2838. 10.1056/NEJMcp041507PubMedCrossRef Poland GA, Jacobson RM: Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med 2004, 351: 2832-2838. 10.1056/NEJMcp041507PubMedCrossRef
3.
go back to reference Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006, 45: 529-538. 10.1016/j.jhep.2006.05.013PubMedCrossRef Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006, 45: 529-538. 10.1016/j.jhep.2006.05.013PubMedCrossRef
4.
go back to reference Nash K: Telbivudine in the treatment of chronic hepatitis B. Adv Ther 2009, 26: 155-169. 10.1007/s12325-009-0004-yPubMedCrossRef Nash K: Telbivudine in the treatment of chronic hepatitis B. Adv Ther 2009, 26: 155-169. 10.1007/s12325-009-0004-yPubMedCrossRef
5.
go back to reference Bryant ML, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra C, Dukhan D, Gosselin G, Imbach JL, Hernandez B, et al.: Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother 2001, 45: 229-235. 10.1128/AAC.45.1.229-235.2001PubMedPubMedCentralCrossRef Bryant ML, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra C, Dukhan D, Gosselin G, Imbach JL, Hernandez B, et al.: Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother 2001, 45: 229-235. 10.1128/AAC.45.1.229-235.2001PubMedPubMedCentralCrossRef
6.
go back to reference Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G, et al.: A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005, 129: 528-536.PubMedCrossRef Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G, et al.: A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005, 129: 528-536.PubMedCrossRef
7.
go back to reference Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, et al.: Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007, 357: 2576-2588. 10.1056/NEJMoa066422PubMedCrossRef Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, et al.: Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007, 357: 2576-2588. 10.1056/NEJMoa066422PubMedCrossRef
8.
go back to reference Tang DC, Xie DM, Xu JJ, He JY, Yao LH, Yang ZZ, Li YF: Clinical Study on Telbivudine Treating Chronic Hepatitis B. Journal of Zhejiang University of Traditional Chinese Medicine 2009, 33: 214-215. Tang DC, Xie DM, Xu JJ, He JY, Yao LH, Yang ZZ, Li YF: Clinical Study on Telbivudine Treating Chronic Hepatitis B. Journal of Zhejiang University of Traditional Chinese Medicine 2009, 33: 214-215.
9.
go back to reference Chen SX, Hu XZ, Zhu F, Wan B, Liu P: Therapeutic effect of 48 weeks of telbivudine on HBeAg-positive chronic hepatitis B. Infect Dis Info 2009, 22: 216-218. Chen SX, Hu XZ, Zhu F, Wan B, Liu P: Therapeutic effect of 48 weeks of telbivudine on HBeAg-positive chronic hepatitis B. Infect Dis Info 2009, 22: 216-218.
10.
go back to reference Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, Wang Y, Zhu L, He Y, Ren H, et al.: Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology 2008, 47: 447-454. 10.1002/hep.22075PubMedCrossRef Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, Wang Y, Zhu L, He Y, Ren H, et al.: Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology 2008, 47: 447-454. 10.1002/hep.22075PubMedCrossRef
11.
go back to reference Zhong XH, Liu Y, Xu C, Xu LM, Wang M, Li MZ: The study of efficacy and side effects of telbivudine and lamivudine for treatment of patients with chronic hepatitis B. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases 2009, 19: 19-21. Zhong XH, Liu Y, Xu C, Xu LM, Wang M, Li MZ: The study of efficacy and side effects of telbivudine and lamivudine for treatment of patients with chronic hepatitis B. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases 2009, 19: 19-21.
12.
go back to reference Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996, 17: 1-12. 10.1016/0197-2456(95)00134-4PubMedCrossRef Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996, 17: 1-12. 10.1016/0197-2456(95)00134-4PubMedCrossRef
13.
go back to reference Cai W: Efficacy and its influent factors of telbivudine or lamivudine treated with chronic hepatitis B patients. Shanghai Jiao Tong University school of medicine 2009. Cai W: Efficacy and its influent factors of telbivudine or lamivudine treated with chronic hepatitis B patients. Shanghai Jiao Tong University school of medicine 2009.
14.
go back to reference Yang JN: A comparison of curative effect between telbivudine and lamivudine in patients with chronic hepatitis B virus. Chin J Prim Med Pharm 2009, 16: 1193-1194. Yang JN: A comparison of curative effect between telbivudine and lamivudine in patients with chronic hepatitis B virus. Chin J Prim Med Pharm 2009, 16: 1193-1194.
15.
go back to reference Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, et al.: 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009, 136: 486-495. 10.1053/j.gastro.2008.10.026PubMedCrossRef Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, et al.: 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009, 136: 486-495. 10.1053/j.gastro.2008.10.026PubMedCrossRef
16.
go back to reference Jia JD, Hou JL, Yin YK, Xu DZ, Tan D, Niu J, Zhou XQ, Wang Y, Zhu L, Brown N: Two-year results of a phase III comparative trial of telbivudine vs lamivudine in chinese patients. Journal of Hepatology 2007, 46: S189-S189. 10.1016/S0168-8278(07)62095-9CrossRef Jia JD, Hou JL, Yin YK, Xu DZ, Tan D, Niu J, Zhou XQ, Wang Y, Zhu L, Brown N: Two-year results of a phase III comparative trial of telbivudine vs lamivudine in chinese patients. Journal of Hepatology 2007, 46: S189-S189. 10.1016/S0168-8278(07)62095-9CrossRef
17.
go back to reference Rasenack J, Poynard T, Lai CL, Gane E, Brown NA, Heathcote J: Efficacy of telbivudine vs lamivudine at 2 years in patinents with HbeAg-positive chronic hepatitis B who are eligible for treatment based on guidelines. Journal of Hepatology 2007, 46: S195-S195. 10.1016/S0168-8278(07)62111-4CrossRef Rasenack J, Poynard T, Lai CL, Gane E, Brown NA, Heathcote J: Efficacy of telbivudine vs lamivudine at 2 years in patinents with HbeAg-positive chronic hepatitis B who are eligible for treatment based on guidelines. Journal of Hepatology 2007, 46: S195-S195. 10.1016/S0168-8278(07)62111-4CrossRef
18.
go back to reference Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11: 97-107. 10.1046/j.1365-2893.2003.00487.xPubMedCrossRef Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11: 97-107. 10.1046/j.1365-2893.2003.00487.xPubMedCrossRef
19.
go back to reference Liaw YF: Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol 2009, 51: 403-410. 10.1016/j.jhep.2009.04.003PubMedCrossRef Liaw YF: Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol 2009, 51: 403-410. 10.1016/j.jhep.2009.04.003PubMedCrossRef
20.
go back to reference Juni P, Altman DG, Egger M: Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001, 323: 42-46. 10.1136/bmj.323.7303.42PubMedPubMedCentralCrossRef Juni P, Altman DG, Egger M: Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001, 323: 42-46. 10.1136/bmj.323.7303.42PubMedPubMedCentralCrossRef
21.
go back to reference Bauer P, Koenig F, Brannath W, Posch M: Selection and bias--two hostile brothers. Stat Med 2010, 29: 1-13.PubMed Bauer P, Koenig F, Brannath W, Posch M: Selection and bias--two hostile brothers. Stat Med 2010, 29: 1-13.PubMed
22.
go back to reference Thornton A, Lee P: Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol 2000, 53: 207-216. 10.1016/S0895-4356(99)00161-4PubMedCrossRef Thornton A, Lee P: Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol 2000, 53: 207-216. 10.1016/S0895-4356(99)00161-4PubMedCrossRef
23.
go back to reference Egger M, Zellweger-Zahner T, Schneider M, Junker C, Lengeler C, Antes G: Language bias in randomised controlled trials published in English and German. Lancet 1997, 350: 326-329. 10.1016/S0140-6736(97)02419-7PubMedCrossRef Egger M, Zellweger-Zahner T, Schneider M, Junker C, Lengeler C, Antes G: Language bias in randomised controlled trials published in English and German. Lancet 1997, 350: 326-329. 10.1016/S0140-6736(97)02419-7PubMedCrossRef
Metadata
Title
Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review
Authors
Shushan Zhao
Lanhua Tang
Xuegong Fan
Lizhang Chen
Rongrong Zhou
Xiahong Dai
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2010
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-7-211

Other articles of this Issue 1/2010

Virology Journal 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine